A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.

被引：2
作者：
Krishnan, Amrita Y.
Shah, Nina
Spira, Alexander I.
Kaufman, Jonathan L.
Niesvizky, Ruben
Shah, Nirav Niranjan
Burke, John M.
Popplewell, Leslie
Martin, Thomas G.
Cheung, Julee
Matheny, Shannon L.
Leonard, John Paul
Molina, Arturo
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Virginia Canc Specialists, Fairfax, VA USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] New York Presbyterian Hosp, Cornell Campus, New York, NY USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Rocky Mt Canc Ctr, Aurora, CO USA
[8] Sutro Biopharma, San Francisco, CA USA
[9] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS7586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7586
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Praluzatamab Ravtansine, a CD166-Targeting Antibody- Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
    Boni, Valentina
    Fidler, Mary J.
    Arkenau, Hendrik-Tobias
    Spira, Alexander
    Meric-Bernstam, Funda
    Uboha, Nataliya
    Sanborn, Rachel E.
    Sweis, Randy F.
    LoRusso, Patricia
    Nagasaka, Misako
    Garcia-Corbacho, Javier
    Jalal, Shadia
    Harding, James J.
    Kim, Stella K.
    Miedema, Iris H. C.
    Vugts, Danielle J.
    Huisman, Marc C.
    Zwezerijnen, Gerben J. C.
    van Dongen, Guus A. M. S.
    van Oordt, C. Willemien Menke van der Houven
    Wang, Song
    Dang, Tam
    Zein, Ivan A.
    Vasiljeva, Olga
    Lyman, Susan K.
    Paton, Virginia
    Hannah, Alison
    Liu, Joyce F.
    CLINICAL CANCER RESEARCH, 2022, 28 (10) : 2020 - 2029
  • [42] Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
    Hamid, Omid
    Chow, Laura Quan Man
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
    Lin, Chia-Chi
    Yang, Tsai-Sheng
    Yen, Chia-Jui
    Cheng, Rebecca
    Liu, Junjun
    Hsu, Chiun
    ONCOLOGIST, 2020, 25 (12) : E1921 - E1929
  • [44] Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody- drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study
    Lu, Shun
    Jian, Hong
    Hong, Wei
    Song, Zhengbo
    Yang, Nong
    Hu, Sheng
    Liang, Zibin
    Wang, Yongsheng
    Wang, Yan
    Peng, Min
    Yu, Yan
    Li, You
    Shuang, Jiapeng
    Zhao, Kaijing
    CANCER RESEARCH, 2023, 83 (08)
  • [45] An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).
    Hillmen, Peter
    Gribben, John G.
    Follows, George A.
    Milligan, Donald W.
    Sayala, Hazem A.
    Moreton, Paul
    Oscier, David
    Dearden, Claire E.
    Kennedy, Daniel B.
    Pettitt, Andrew R.
    Nathwani, Amit
    Cohen, Dena
    Gregory, Walter M.
    Rawstron, Andy C.
    Hayward, Colin R. W.
    Pocock, Christopher
    BLOOD, 2009, 114 (22) : 1331 - 1332
  • [46] Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
    Cheah, Chan Yoon
    Belada, David
    Fanale, Michelle A.
    Janikova, Andrea
    Czucman, Myron S.
    Flinn, Ian W.
    Kapp, Amy V.
    Ashkenazi, Avi
    Kelley, Sean
    Bray, Gordon L.
    Holden, Scott
    Seymour, John F.
    LANCET HAEMATOLOGY, 2015, 2 (04): : E166 - E174
  • [47] Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies
    Budde, Elizabeth
    Gopal, Ajay K.
    Flinn, Ian W.
    Nastoupil, Loretta J.
    Gordon, Michael S.
    Pang, Ching-Fai
    Keyt, Bruce
    Carroll, Steve
    Leabman, Maya
    Hernandez, Genevive
    Sison, Iris
    Chen, Daniel
    Godfrey, Wayne
    Armand, Philippe
    BLOOD, 2020, 136
  • [48] A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies
    Olszewski, Adam
    Kahn, David
    Yoo, Brian
    Tan, Joanne B. L.
    Gupta, Vipul K.
    Schuck, Edgar
    Nie, Zhe
    Krilov, Goran
    Wright, D. Hamish
    Weiss, Daniel
    Lachowicz, Jean
    Akinsanya, Karen
    Yin, Wu
    BLOOD, 2023, 142
  • [49] waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.
    Zinzani, Pier Luigi
    Mayer, Jiri
    Benjamini, Ohad
    Berkovits, Alejandro
    Glimelius, Ingrid
    Stevens, Don A.
    Chaudhry, Arvind
    Demir, Ahmet Muzaffer
    Sanz, Ramon Garcia
    Kim, Won Seog
    Li, Fei
    Halka, Janusz
    Marin-Niebla, Ana
    Ozcan, Muhit
    Paszkiewicz-Kozik, Ewa
    Santoro, Armando
    Ren, Yixin
    Ogbu, Uzor
    Marinello, Patricia
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] A multi-center, open-label phase 1/1b dose finding, safety, and pharmacokinetic study of MBRC-101, an Anth-EphA5 monomethyl auristatin (MMAE) antibody drug conjugate, in advanced refractory solid tumors.
    Sen, Shiraj
    Salkeni, Mohamad Adham
    Albany, Costantine
    Gandhi, Neel Jitendra
    Edenfield, William Jeffery
    Parsons, Kellogg
    Chen, Isan
    Powderly, John D., II
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345